<DOC>
	<DOC>NCT00651703</DOC>
	<brief_summary>The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine alone or in combination with different adjuvants.</brief_summary>
	<brief_title>Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Histological confirmed Stage III or IV malignant melanoma HLAA*0201 haplotype Expected survival of at least 9 months Willing and able to comply with all trial requirements (e.g. diaries, CTs) Given written informed consent Females only if nonreproductive or if they agree to consistently practice an effective and accepted method of contraception Any contraindication to any study related test or assessment Current or planned use of contraindicated concomitant medication Presence or history of relevant cardiovascular, renal, pulmonary, endocrine, autoimmune, neurological and psychiatric disease Infection with HIV, HBV or HCV Pregnancy or lactation or females planning to become pregnant during the study Abuse of alcohol or other drugs Use of investigational drug within 30 days before enrolment Previous participation in a clinical trial with a Qbbased Cytos vaccine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>